General
Preferred name
CEFOPERAZONE
Synonyms
CP 52640-2 ()
CEFOPERAZONE SODIUM ()
Cefob ()
Medocef ()
CEFOPERAZONE DIHYDRATE ()
cefoperazone ()
Cefobis ()
Cefoperaone Sodium Salt ()
Cefoperazone (sodium salt) ()
Cefoperazone sodium salt ()
Peracef ()
Cefoperazona ()
CP-52,640-2 ()
NSC-758173 ()
Cefoperazone (as sodium) ()
T-1551 ()
CP-52640-2 ()
CP-526402 ()
Sodium cefoperazone ()
Cefobid ()
Cefoperazone sodium component of sulperazone ()
P&D ID
PD010964
CAS
62893-19-0
62893-20-3
Tags
available
covalent binder
drug
Approved by
FDA
First approval
1982
Drug indication
osteomyelitis
Bacterial infection
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Indicated for the treatment of following infections caused by susceptible bacteria:[label]; ; 1) Respiratory tract infections caused by _S. pneumoniae_, _H. influenzae_, _S. aureus_ (penicillinase and non-penicillinase producing strains), _S. pyogenes_ (Group A beta-hemolytic streptococci), _P. aeruginosa_, _Klebsiella pneumoniae_, _E. coli_, _Proteus mirabilis_, and Enterobacter species.; ; 2) Peritonitis and other intra-abdominal infections caused by _E. coli_, _P. aeruginosa_, and anaerobic gram-negative bacilli (including _Bacteroides fragilis_).; ; 3) Bacterial septicemia caused by _S. pneumoniae_, _S. agalactiae_, _S. aureus_, _Pseudomonas aeruginosa_, _E. coli_, _Klebsiella_ spp., _Klebsiella pneumoniae_, Proteus species (indole-positive and indole-negative), _Clostridium_ spp. and anaerobic gram-positive cocci.; ; 4) Infections of the skin and skin structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa.; ; 5) Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci.; ; 6) Urinary tract infections caused by Escherichia coli and Pseudomonas aeruginosa.; ; 7) Enterococcal Infections. Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, _in vitro_ susceptibility testing may not correlate directly with _in vivo_ results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.
DESCRIPTION
Cefoperazone is a semisynthetic, third generation cephalosporin and belongs to the β-lactam class of antibacterial compounds .
(GtoPdb)
DESCRIPTION
Cefoperazone, a semisynthetic cephalosporin, has a broad spectrum of antibacterial activity[1].
PRICE
29
DESCRIPTION
Cefoperazone (Medocef) binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. It can inhibit rMrp2-mediated [3H]E217??G uptake (IC50: 199 ??M).
PRICE
29
DESCRIPTION
Cefoperazone sodium salt (CP 52640-2), a semisynthetic cephalosporin, has a broad spectrum of antibacterial activity[1].
DESCRIPTION
Cefoperazone is a broad-spectrum cephalosporin antibiotic used for the treatment of bacterial infections in various locations, including the respiratory tract, abdomen, skin, and female genital tracts.
(Enamine Bioactive Compounds)
DESCRIPTION
Cefoperazone (Medocef) binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. It can inhibit rMrp2-mediated [3H]E217βG uptake (IC50: 199 μM).
(TargetMol Bioactive Compound Library)
DESCRIPTION
Cefoperazone sodium salt (CP 52640-2) is a broad-spectrum cephalosporin with a tetrazolyl moiety, utilized for the treatment of Pseudomonas infections.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
Natural product-based probes and drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
69
Molecular Weight
645.14
Hydrogen Bond Acceptors
13
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
5
Aromatic Ring Count
2
cLogP
-1.11
TPSA
220.26
Fraction CSP3
0.4
Chiral centers
3.0
Largest ring
6.0
QED
0.14
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Bacterial
PBPs
Antibacterial
Antibiotics,Bacterial
Indication
gram-negative bacterial infections
MOA
bacterial cell wall synthesis inhibitor
ATC
J01DD62
J01DD12
Biosynthetic Origin
Peptide (beta-Lactam)
Therapeutic Class
Antimicrobial
Antibiotics
Pathway
Microbiology/virology
Anti-infection
Source data
